![Elaine Benaksas](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Elaine Benaksas
Corporate Officer/Principal at American Chemical Society
Elaine Benaksas active positions
Companies | Position | Start | End |
---|---|---|---|
American Chemical Society
![]() American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Corporate Officer/Principal | - | - |
Career history of Elaine Benaksas
Former positions of Elaine Benaksas
Companies | Position | Start | End |
---|---|---|---|
Encore Pharmaceuticals, Inc.
![]() Encore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encore Pharmaceuticals, Inc. (EPI) is a drug discovery and development company with advanced proprietary products for the treatment and prevention of cancer and neurologic and cardiovascular diseases. EPI's principal drug innovations have come from discoveries made by researchers at Loma Linda University Medical Center (LLUMC). EPI was founded in 1997 and concluded a technology transfer license agreement with LLUMC in January 1999. The discovery operation continues to be located in the LLUMC environment where operations in 1999 were expanded to include clinical development of EPI's lead drug candidate E-7869 (now known as MPC-7869) for treatment of prostate and colon cancer. The company's research efforts have also led to the discovery of a -tocopherol (member of the Vitamin E family) metabolite designated as E-8110 (also known as LLU- ) and bioanalogs which have natriuretic (sodium excretion) activity. These compounds are being examined for their anti-hypertensive, anti-oxidant and anti-cancer properties. Patent applications for EPI drug discoveries have been filed and are in review worldwide | Chief Tech/Sci/R&D Officer | 2010-12-16 | - |
Loma Linda University | Corporate Officer/Principal | - | - |
Training of Elaine Benaksas
University of California, Los Angeles | Doctorate Degree |
Statistics
International
United States | 5 |
Operational
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectoral
Consumer Services | 3 |
Commercial Services | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
American Chemical Society
![]() American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Commercial Services |
Encore Pharmaceuticals, Inc.
![]() Encore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encore Pharmaceuticals, Inc. (EPI) is a drug discovery and development company with advanced proprietary products for the treatment and prevention of cancer and neurologic and cardiovascular diseases. EPI's principal drug innovations have come from discoveries made by researchers at Loma Linda University Medical Center (LLUMC). EPI was founded in 1997 and concluded a technology transfer license agreement with LLUMC in January 1999. The discovery operation continues to be located in the LLUMC environment where operations in 1999 were expanded to include clinical development of EPI's lead drug candidate E-7869 (now known as MPC-7869) for treatment of prostate and colon cancer. The company's research efforts have also led to the discovery of a -tocopherol (member of the Vitamin E family) metabolite designated as E-8110 (also known as LLU- ) and bioanalogs which have natriuretic (sodium excretion) activity. These compounds are being examined for their anti-hypertensive, anti-oxidant and anti-cancer properties. Patent applications for EPI drug discoveries have been filed and are in review worldwide | Health Technology |
- Stock Market
- Insiders
- Elaine Benaksas
- Experience